Posted inDaily Brief

Qualicorp Misses Target

A busy week for Brazilian equity issuance got off to a shaky start Monday after Qualicorp priced a BRL1.08bn ($677.6m) IPO well below the range. The Brazilian health benefits provider priced at BRL13 per share against a range of BRL16-BRL19. The company sold 27.2m primary shares and 56.2m secondary shares held by Carlyle and Jose Seripieri Filho, which respectively hold 69% and 31% stakes in the company. “People were saying it looked a little expensive,” says New York-based EM equity investor, who cited valuation levels and uncertainty over Qualicorp’s business model as reasons for not participating. The deal raised only BRL353.6m for the company, which had been looking to garner as much as BRL476m if it had priced at its midpoint. Qualicorp’s difficulties may be another sign that investors are starting to suffer from deal fatigue. Only last week Chilean healthcare provider Cruz Blanca’s IPO also failed to live up to expectations when it priced at CLP500 a share after setting a CLP525 minimum, investors say. This comes after Brazil Pharma came at the low end of its BRL16.25-BRL19.25 range last week, drawing only BRL17.25. Qualicorp’s investor meetings had been well attended with crossover interest looking to gain exposure to the Brazilian heathcare sector. Most of the book came from the US, with significant interest from US healthcare investors. Carlyle only acquired its stake in 2010, in a deal that valued the company at $1.2bn. Qualicorp, founded in 1997, recorded Ebitda of BRL127.5m in 2010, up from BRL56.4m in 2009.Bank of America Merrill Lynch, Bradesco, Credit Suisse and Goldman Sachs managed the sale. Proceeds from the primary portion are slated for general corporate purposes, such as the leasing or acquisition of equipment and material, as well as geographic expansion.

Posted inDaily Brief

Technos Heard Oversubscribed Ahead of IPO

Technos’s book was heard to be oversubscribed Monday afternoon ahead of its planned IPO today, but investors were become increasingly selective as they braced for a string of equity deals this week. The Brazilian watchmaker is offering 10.9m primary and 13.4m secondary shares at BRL16.50-BRL20.50 each. At the BRL18.50 midpoint, that would mean a BRL517m ($323m) size, assuming the exercise of a 15% greenshoe. A 20% hot issue is also available. A New York-based EM equity investor thought the IPO looked small and was likely to pass, but believed it should generate interest among domestic accounts. Investors are somewhat spoilt for choice given the abundance of Brazilian equity issuance due this week, including follow-ons from BR Properties, Kroton and Mahle, as well as IPOs from Perenco and Qualicorp. Barclays, Credit Suisse, Goldman Sachs and Itau are managing the sale. The company generated BRL59.1m in Ebitda in 2010. Proceeds from the primary offering will go to finance the company’s growth plan, including potential acquisitions, payment of the acquisition of shares and to repay a loan with HSBC.

Posted inDaily Brief

LatAm Equity Funds See Outflows

LatAm equity funds saw $424m in outflows for the week ended June 22, according to EPFR Global. EM equity funds, meanwhile, had $340m in outflows. Performance was mixed, as EM funds fell 0.06% for the week ended June 23, and are down 3.85% ytd, according to Lipper. Meanwhile, LatAm funds rose by 1.17% for the week, while still remaining lower by 5.95% ytd. Global small and mid-cap funds also rose 0.89% for the week, and are up 0.41% ytd.

Posted inDaily Brief

Brazil ECM Braces for Busy Week

Brazilian equity issuers are back in full swing and are set this week to bring 6 deals, which together could raise in up to BRL4.3bn ($2.7bn) and truly break what has been a brief lull in activity. ECM Bankers foresee continued demand for offerings despite some complaints about broader issuance fatigue. With commodities plays on the Bovespa unlikely to offer much near-term upside and a chunk of the index containing less-than-stellar companies, investors are on the hunt for quality Brazilian stocks that can still provide some capital gains, not mention diversity, a Sao Paulo-based banker says. After Brazil Pharma helped to reopen the market last week with a BRL466m IPO, health insurance provider Qualicorp is preparing to price today an IPO that could raise BRL1.46bn if done at the midpoint of a BRL16-BRL19 range. Carlyle Group and one company official are selling 45.5m secondary shares, to go with the 27.2m new shares to raise funds for acquisitions in the health plan area and general purposes. Bank of America Merrill Lynch, Bradesco, Credit Suisse and Goldman Sachs are managing the sale. Tomorrow is also scheduled to see a follow-on from BR Properties that is targeting about BRL700m, as well as an IPO from watchmaker Technos that would raise BRL517m at the midpoint of a BRL16.50-BRL20.50 range. Education company Kroton is eyeing a follow-on of about BRL450m Wednesday, and Mahle-Metal Leve should follow with a more than BRL350m selldown of secondary shares owned by its German parent Thursday. An IPO from E&P operator Perenco Brasil could fetch BRL750m-BRL850m on Friday to close out the week. Energias do Brasil is also set to hold an approximately BRL750m follow-on sale of Energias de Portugal shares July 7.

Posted inDaily Brief

TPI Plans Local Inflation Linker

Brazil’s Triunfo Participacoes e Investimentos (TPI) plans to raise a BRL180m ($113m) bond in the domestic market. The 2018 will be indexed to IPCA and pay 8.65% per year. Proceeds will go towards investments at the Brazilian conglomerate’s subsidiaries, which include energy generators, port operators and concessionaire Empresa Concessionaria de Rodovias do Norte. Mandated banks on the restricted rule 476 bond have not been named.

Posted inDaily Brief

Cruz Blanca IPO Misses Expectations

Chilean health-care provide Cruz Blanca has priced a CLP111.0bn ($234m) IPO below its floor price, raising less than the $250m anticipated by the market. The 122m primary and 100m secondary share sale priced at CLP500 each, with the issuer opting to come below the CLP525 minimum floor that it had set earlier. Analysts had recommended buying at up to CLP550-CLP600, well above the CLP497.81 closing price on the first day of trading. Total demand came in at CLP444.9bn from 1,348 orders. Retail accounted for 14% of demand, 4.5% went to employees and others linked to Cruz Blanca, with the remainder going to Chilean and international non-retail investors. The sale adds diversity to Chile’s health sector, seen as a play on growth and rising incomes, with spending in the sector expected to double in the next 10 years. Sixty five percent of the proceeds are slated for investments as the company looks to grow through acquisitions and organically. It has plans to open new locations for its Integramedica walk-in clinics as well as renovate its 3 brands of medical centers. The other 35% will go to repay debt. Bice, Celfin and IMTrust managed the sale. The issuer, owned by Grupo Said and Linzor Capital, was founded in 1999, though the Cruz Blanca brand was created in 2008 with the acquisition of health insurer Isapre ING. The health insurance operations represent 74% of Cruz Blanca’s business. Cruz Blanca claims 20% of the market in Chile, covering 530,000 people.

Posted inDaily Brief

EDP Changes Timing for EDB Selldown

EDP – Energias do Brasil has moved the date of its planned follow-on to July 7 from June 29. The Brazilian electricity company refiled its prospectus with the local stock exchange and expects to raise around BRL750m ($471m) based on the stock’s closing price of BRL37.59 on June 15. The bookbuilding process will begin July 4 and end July 6, for the sale of 19.9m shares. A 10% greenshoe is also possible. The Portuguese utility EDP would reduce its 49.1% stake in EDB to 35.3% if the sale includes the 10% overallotment, with the free float increasing to 48.8% from 35.0%. Espirito Santo, Itau, Morgan Stanley and Santander are leads. EDP said in March that it aims to raise EUR500m though asset sales this year.

Posted inDaily Brief

Cruz Blanca Set for IPO

Chile’s Cruz Blanca is set to announce pricing today on its IPO and could raise more than $250m. Market expectations are for a CLP550-CLP600 per share price for the sale of 122m in primary shares and up to 100m in secondary shares, implying a size of anywhere between CLP122.1bn-133.2bn ($258m-$281m). Local brokerage Security sees health-care spending doubling over the next 10 years and recommends buying the IPO at CLP560 with a 12-month target of CLP700. The health services provider has been marketing in LatAm, the US and UK, as it prepares to float up to 35% of the company. It follows pharmaceutical company CF Recalcine, which raised $368m equivalent last month, adding some sorely needed diversity to Chile’s equity market. Like Recalcine, Cruz Blanca is an expansion play, with 65% of proceeds slated for investments. The company is looking to grow through acquisitions and organically and has plans to open new locations for its Integramedica walk-in clinics as well as renovate its 3 brands of medical centers. The other 35% would be used to repay debt. Bice, Celfin and IMTrust are managing the sale. The issuer, owned by Grupo Said and Linzor Capital, was founded in 1999, though the Cruz Blanca brand was created in 2008 with the acquisition of health insurer Isapre ING. The health insurance operations represent 74% of Cruz Blanca’s business, according to the prospectus. Its total 2010 Ebitda was $31.2m equivalent. Cruz Blanca claims 20% of the market in Chile, covering 530,000 people, according to its website.

Gift this article